Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

Merck & Co has followed the lead of other big pharma groups like Pfizer and GlaxoSmithKline by hiving off its mature and off-patent drugs into a new company. The decision will take some 90 ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its ...

Merck will put BioAI through its paces as a way to identify if new drug candidates pose a risk of liver toxicity, focusing on compounds with known issues that regular preclinical testing was ...

Both easily beat forecasts. Sales of its popular cancer drug, Keytruda, gained 19.9% to $6.95 billion. Merck said that was driven by increased demand for use in earlier-stage indications and ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025 On Wednesday, Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of ...